Oral versus Intravenous Antibiotics for Bone and Joint Infection

被引：550

作者：

Li, H. -K. ^{[1
,5
]}

Rombach, I. ^{[2
]}

Zambellas, R. ^{[2
]}

Walker, A. S. ^{[6
]}

McNally, M. A. ^{[1
]}

Atkins, B. L. ^{[1
]}

Lipsky, B. A. ^{[4
]}

Hughes, H. C. ^{[10
]}

Bose, D. ^{[11
]}

Kumin, M. ^{[3
]}

Scarborough, C. ^{[3
]}

Matthews, P. C. ^{[1
,3
]}

Brent, A. J. ^{[1
,3
]}

Lomas, J. ^{[1
]}

Gundle, R. ^{[1
]}

Rogers, M. ^{[1
]}

Taylor, A. ^{[1
]}

Angus, B. ^{[1
,3
]}

Byren, I. ^{[1
]}

Berendt, A. R. ^{[1
]}

Warren, S. ^{[7
,13
]}

Fitzgerald, F. E. ^{[13
]}

Mack, D. J. F. ^{[7
,13
]}

Hopkins, S. ^{[7
]}

Folb, J. ^{[14
]}

Reynolds, H. E. ^{[14
]}

Moore, E. ^{[15
]}

Marshall, J. ^{[15
]}

Jenkins, N. ^{[12
]}

Moran, C. E. ^{[12
]}

Woodhouse, A. F. ^{[12
]}

Stafford, S. ^{[12
]}

Seaton, R. A. ^{[16
]}

Vallance, C. ^{[16
]}

Hemsley, C. J. ^{[8
]}

Bisnauthsing, K. ^{[8
]}

Sandoe, J. A. T. ^{[18
]}

Aggarwal, I. ^{[19
]}

Ellis, S. C. ^{[20
]}

Bunn, D. J. ^{[20
]}

Sutherland, R. K. ^{[21
]}

Barlow, G. ^{[22
]}

Cooper, C. ^{[2
]}

Geue, C. ^{[17
]}

McMeekin, N. ^{[17
]}

Briggs, A. H. ^{[17
]}

Sendi, P. ^{[23
]}

Khatamzas, E. ^{[1
]}

Wangrangsimakul, T. ^{[1
]}

Wong, T. H. N. ^{[1
]}

机构：

[1] Oxford Univ Hosp NHS Fdn Trust, Oxford, England

[2] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England

[3] Univ Oxford, Dept Med, Oxford, England

[4] Univ Oxford, Div Med Sci, Oxford, England

[5] Imperial Coll London, Div Infect Dis, London, England

[6] UCL, Med Res Council Clin Trials Unit, London, England

[7] Royal Free London NHS Fdn Trust, London, England

[8] Guys & St Thomas NHS Fdn Trust, London, England

[9] Publ Hlth England, London, England

[10] Univ Wales Hosp, Cardiff, S Glam, Wales

[11] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[12] Heart England NHS Fdn Trust, Birmingham, W Midlands, England

[13] Royal Natl Orthopaed Hosp NHS Trust, Stanmore, Middx, England

[14] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool, Merseyside, England

[15] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[16] Queen Elizabeth Univ Hosp, NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland

[17] Univ Glasgow, Hlth Econ & Hlth Technol Assessment, Glasgow, Lanark, Scotland

[18] Univ Leeds, Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England

[19] Ninewells Hosp, NHS Tayside, Dundee, Scotland

[20] Northumbria Healthcare NHS Fdn Trust, Northumberland, England

[21] Western Gen Hosp, NHS Lothian, Edinburgh, Midlothian, Scotland

[22] Hull & East Yorkshire Hosp NHS Trust, Kingston Upon Hull, N Humberside, England

[23] Univ Bern, Bern, Switzerland

[24] Univ Oxford, Clin Res Unit, Wellcome Trust, Ho Chi Minh City, Vietnam

[25] Kenya Med Res Inst KEMRI, Wellcome Trust Res Programme, Kilifi, Kenya

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2019年 / 380卷 / 05期

关键词：

OSTEOMYELITIS;

D O I：

10.1056/NEJMoa1710926

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND The management of complex orthopedic infections usually includes a prolonged course of intravenous antibiotic agents. We investigated whether oral antibiotic therapy is noninferior to intravenous antibiotic therapy for this indication. METHODS We enrolled adults who were being treated for bone or joint infection at 26 U.K. centers. Within 7 days after surgery (or, if the infection was being managed without surgery, within 7 days after the start of antibiotic treatment), participants were randomly assigned to receive either intravenous or oral antibiotics to complete the first 6 weeks of therapy. Follow-on oral antibiotics were permitted in both groups. The primary end point was definitive treatment failure within 1 year after randomization. In the analysis of the risk of the primary end point, the noninferiority margin was 7.5 percentage points. RESULTS Among the 1054 participants (527 in each group), end-point data were available for 1015 (96.3%). Treatment failure occurred in 74 of 506 participants (14.6%) in the intravenous group and 67 of 509 participants (13.2%) in the oral group. Missing end-point data (39 participants, 3.7%) were imputed. The intention-to-treat analysis showed a difference in the risk of definitive treatment failure (oral group vs. intravenous group) of -1.4 percentage points (90% confidence interval [CI], -4.9 to 2.2; 95% CI, -5.6 to 2.9), indicating noninferiority. Complete-case, per-protocol, and sensitivity analyses supported this result. The between-group difference in the incidence of serious adverse events was not significant (146 of 527 participants [27.7%] in the intravenous group and 138 of 527 [26.2%] in the oral group; P=0.58). Catheter complications, analyzed as a secondary end point, were more common in the intravenous group (9.4% vs. 1.0%). CONCLUSIONS Oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first 6 weeks for complex orthopedic infection, as assessed by treatment failure at 1 year.

引用

页码：425 / 436

页数：12

共 50 条

[1] Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT
Scarborough, Matthew
Li, Ho Kwonn
Rombach, Ines
Zambellas, Rhea
Walker, A. Sarah
McNally, Martin
Atkins, Bridget
Kumin, Michelle
Lipsky, Benjamin A.
Hughes, Harriet
Bose, Deepa
Warren, Simon
Mack, Damien
Folb, Jonathan
Moore, Elinor
Jenkins, Neil
Hopkins, Susan
Seaton, R. Andrew
Hemsley, Carolyn
Sandoe, Jonathan
Aggarwal, Ila
Ellis, Simon
Sutherland, Rebecca
Geue, Claudia
McMeekin, Nicola
Scarburough, Claire
Paul, John
Cooke, Graham
Bostock, Jennifer
Khatamzas, Elham
Wong, Nick
Brent, Andrew
Lomas, Jose
Matthews, Philippa
Wangrangsimakul, Tri
Gundle, Roger
Rogers, Mark
Taylor, Adrian
Thwaites, Guy E.
Bejon, Philip
HEALTH TECHNOLOGY ASSESSMENT, 2019, 23 (38) : 1 - +
[2] Oral Versus Intravenous Antibiotics for Pediatric Osteoarticular Infection: When and to Whom?
Alcobendas Rueda, Rosa M.
Nunez, Esmeralda
Martin, Laura
Belen Hernandez, Maria
Saavedra-Lozano, Jesus
Udaondo, Clara
Murias, Sara
Remesal, Agustin
Calvo, Cristina
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2022, 41 (09) : E351 - E357
[3] Endocarditis: oral versus intravenous antibiotics
Alexandra Le Bras
Nature Reviews Cardiology, 2018, 15 : 653 - 653
[4] Endocarditis: oral versus intravenous antibiotics
Le Bras, Alexandra
NATURE REVIEWS CARDIOLOGY, 2018, 15 (11) : 653 - 653
[5] Oral versus Intravenous Antibiotics for Endocarditis
不详
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12): : 1141 - 1143
[6] Intravenous versus oral antibiotics for urinary tract infections
Hopp, L
PEDIATRICS, 2000, 106 (04) : 865 - 865
[7] Urinary tract infection and antibiotics: Oral or intravenous route?
Bacchetta, J.
Cochat, P.
ARCHIVES DE PEDIATRIE, 2008, 15 (08): : 1375 - 1377
[8] Oral Antibiotics Are Equal to IV Antibiotics for Serious Bone and Joint Infections
Ebell, Mark H.
AMERICAN FAMILY PHYSICIAN, 2019, 100 (07) : 441 - 442
[9] Intravenous Versus Oral Antibiotics for Postdischarge Treatment of Complicated Pneumonia
Shah, Samir S.
Srivastava, Rajendu
Wu, Susan
Colvin, Jeffrey D.
Williams, Derek J.
Rangel, Shawn J.
Samady, Waheeda
Rao, Suchitra
Miller, Christopher
Cross, Cynthia
Clohessy, Caitlin
Hall, Matthew
Localio, Russell
Bryan, Matthew
Wu, Gong
Keren, Ron
PEDIATRICS, 2016, 138 (06)
[10] Oral versus intravenous antibiotics in treatment of paediatric febrile neutropenia
Vedi, Aditi
Cohn, Richard
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2013, 49 (03) : 170 - 178

← 1 2 3 4 5 →